Citadel Advisors’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Citadel Advisors’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,740	Closed	-$2.22K	–	15761
2023 Q1	$2.22K	Sell	12,740 -20,208	-61%	-$11.2K	﹤0.01%	14177
2022 Q4	$13.1K	Buy	+32,948	New	+$21.7K	﹤0.01%	13469
2022 Q2	–	Sell	-32,045	Closed	-$113K	–	14624
2022 Q1	$201K	Buy	+32,045	New	+$201K	﹤0.01%	11537

Citadel Advisors's CDAK Position: Q2 2023 in Review

Citadel Advisors sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 12,740 shares — an estimated $2.22K sold.

Citadel Advisors first reported a position in CDAK in Q1 2022 and held it in 3 quarters. The position peaked at $201K in Q1 2022. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

Citadel Advisors reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 12,740 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $2.22K.
Citadel Advisors first reported a position in Codiak BioSciences, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
Citadel Advisors's Codiak BioSciences, Inc. Common Stock position peaked at $201K in Q1 2022.
1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.